TopoTarget reports promising acne drug results and seeks partner  

2006.04.06
Danish biopharmaceutical company TopoTarget has reported promising phase II trial results with Avugane, a novel gel-based formulation for the treatment of acne, and seeks licensing partner

Danish biopharmaceutical company TopoTarget, which specialises in cancer research, has reported promising phase II trial results with Avugane, a novel gel-based formulation for the treatment of acne vulgaris, the most common inflammatory skin disorder among adolescents. Approx. 80% of adolescents show signs of acne in various degrees, while 15% suffers so severely that they need medical treatment. Avugane is part of TopoTarget's cancer research, but now turns out also to be effective for treating acne vulgaris.

Peter Buhl Jensen, managing director of TopoTarget says: "Acne vulgaris represents a significant unmet medical need and we are very encouraged by the results. We aim to continue development of this promising drug while we are seeking an out-licensing partner with expertise in dermatology." He emphasises that the market for acne treatment has not seen new products for a number of years.

Current topical therapies for all forms of acne are estimated to generate USD 1.5 bn in annual sales in the US alone. The news was reported by financial daily newspaper Børsen and in a TopoTarget press release.

TopoTarget was established in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has operations in Oxford UK, and in Frankfurt and Karlsruhe, Germany.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×